Navigation Links
Anthera Announces Initiation of BRIGHT-SC Phase 2 Clinical Study in IgA Nephropathy with Blisibimod
Date:6/24/2013

p>

About B-Cell Activating Factor (BAFF) and Blisibimod

BAFF has been associated with a wide range of B-cell-mediated autoimmune diseases, including systemic lupus erythematosus, IgA nephropathy, lupus nephritis, rheumatoid arthritis, multiple sclerosis, Sjogren's Syndrome, Graves' Disease and others. Multiple clinical studies with other BAFF antagonists recently have reported on the potential positive role on BAFF inhibitors in treating lupus and rheumatoid arthritis with concomitant decreases in B-cells, plasma cells and autoantibodies. Anthera is advancing its development of blisibimod, a broad inhibitor of BAFF, to expand its potential clinical utility in autoimmune diseases. Blisibimod is a novel protein compromised of high-affinity BAFF binding domains fused to a human Fc domain, called a peptibody and is distinct from an antibody. Anthera owns worldwide rights to blisibimod in all potential indications.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune disorders.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements about the Company's expectations with respect to its proposed offering, including its intention to offer and sell shares, its intention to grant the underwriters an option to purchase additional shares and its intended use of proceeds from the offering.  Such statements are based on the Company's e
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
2. Anthera Announces First Quarter 2012 Financial Report and Conference Call
3. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
4. Anthera Updates Phase 3 Plans Following Results from the Phase 2b PEARL-SC Dose Ranging Study of Blisibimod
5. Anthera Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
6. Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 Population
7. Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
8. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
9. Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
10. Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update
11. Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)...  Ascendant Solutions, Inc. (Pink Sheets: ASDS ) ... subsidiary, Dougherty,s Holdings, has acquired Springtown Drug (" ... Springtown, Texas , just north of ... pharmacy has provided retail prescriptions, healthcare products and gifts ... . The Springtown ...
(Date:8/31/2015)... Pa. , Aug. 31, 2015 The ... reversed statewide since Pennsylvania State ... life-saving drug kits, naloxone. Heroin and opioid ... Pennsylvania , killing more individuals than ... approximately 2,400 Pennsylvanians died from a drug overdose. ...
(Date:8/31/2015)... , Aug. 31, 2015 Regen BioPharma, ... development of a novel means of delivering its ... RGBP-248, to liver tumors utilizing a clinically approved ... overcomes previous hurdles with gene silencing therapeutics in ... delivered throughout the whole body.  By utilizing a ...
Breaking Medicine Technology:Ascendant Solutions, Inc. Announces Completion of Fifth Pharmacy Acquisition by Its Dougherty's Holdings Subsidiary 2Ascendant Solutions, Inc. Announces Completion of Fifth Pharmacy Acquisition by Its Dougherty's Holdings Subsidiary 3Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 2Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 3Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3
... June 9 Halozyme Therapeutics,Inc. (Nasdaq: ... products targeting the extracellular matrix, today,announced new ... mellitus program at,the American Diabetes Association,s 68th ... company,s proprietary recombinant human,hyaluronidase enzyme (rHuPH20) with ...
... Pivotal Study Highlighted at Recent Arizona Alzheimer,s ... Consortium Annual Conference in Phoenix -, PHOENIX and ... Health Research Institute today announced that they are,actively enrolling patients ... treatment of Alzheimer,s disease. The study will,evaluate the safety and ...
Cached Medicine Technology:Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 2Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 3Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 4Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 5Banner Alzheimer's Institute and Sun Health Research Institute Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimer's Disease 2Banner Alzheimer's Institute and Sun Health Research Institute Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimer's Disease 3
(Date:9/1/2015)... ... 01, 2015 , ... Dr. Trace Curry successfully placed one of the first ... last month the FDA has approved two intra-gastric balloons, the ORBERA ™ Managed ... first incisionless, reversible, weight loss procedures available to Americans. , Dr. Curry, ...
(Date:9/1/2015)... ... September 01, 2015 , ... Elizabeth Callahan, MD, founder and medical director of ... area to offer RADIESSE® filler treatment for volume loss in the hands. RADIESSE provides ... veins in the hands, delivering smooth, natural-looking results that can last up to one ...
(Date:9/1/2015)... ... ... September is Baby Safety Month, and Lightning Labels wants to make ... safety top of mind at all times. , Sponsored by the Juvenile Products Manufacturers ... Baby Safety Zone website, this year's theme is A Room with A Safe View, ...
(Date:8/31/2015)... ... 01, 2015 , ... The PT Outcomes Registry is an organized system for ... patients. The Registry is being developed by the American Physical Therapy Association (APTA). , ... be selected to contribute FOTO Outcomes measures as one of the primary global outcomes ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... updated to include a wealth of information for specific translation services within the ... expertise and an incredible track record of successful work. , ITC Global Translations ...
Breaking Medicine News(10 mins):Health News:Dr. Trace Curry Performs First ORBERA™ Intra-gastric Balloon in Ohio at JourneyLite, a New Incisionless Option For The Treatment of Obesity 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 3Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 3Health News:FOTO Selected as Official Registry Partner with Physical Therapy Outcomes Registry 2Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 2Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 3
... , ... Medical Team Provides High Quality, Cost Effective Occupational Health Care , ... Pittsburgh, PA (PRWEB) April 18, 2010 ... care facilities, is an organization of physicians and health care professionals whose mission is ...
... past generations, study finds , FRIDAY, April 16 (HealthDay News) ... and failing to lose the extra pounds for longer, researchers ... worse than previously estimated. , The study authors report ... became obese -- a step above merely overweight -- when ...
... ... Westminster’s Arbor Day and Earth Day Celebration Saturday, April 17. , ... Golden, CO (PRWEB) April 17, 2010 -- Panorama ... celebrate Earth Day and Arbor Day April 17. As part of its companywide green initiative, ...
... ... way doctors do, whether this means using EMR based handwritten notes, point and click ... or Nightingale transcription service. , ... Markham, ON (PRWEB) April 17, 2010 -- Nightingale is proud to sponsor ...
... who live along the U.S.-Mexico border frequently buy over-the-counter ... a prescription and can send a friend to pick ... from two University of Texas campuses and Ibis Reproductive ... area, suggests there is demand in the United States ...
... Despite ... the standard of care dropping in the United States. PeriGen’s Knowledge Summit’s speakers will discuss ... ... study in Lancet claims that maternal mortality rates around the world are going down. That ...
Cached Medicine News:Health News:Allegheny Medical's Occupational Health Services Helps Employers Build a Healthier Workforce 2Health News:Allegheny Medical's Occupational Health Services Helps Employers Build a Healthier Workforce 3Health News:Obesity Epidemic May Cut Life Spans of Young Adults 2Health News:Panorama Orthopedics and the City of Westminster Join Forces to Improve the Environment through Tree Giveaway 2Health News:Canadian EMR Vendor Nightingale Exhibiting at Spring 2010 Canada Health Infoway Partnership Conference 2Health News:Convenience drives US women to buy over-the-counter contraception in Mexico, study finds 2Health News:PeriGen Knowledge Summit to Address Issues in Maternal Healthcare 2